Oral Oncology Inventory Management Interventions by a Specialty Pharmacy

Marjorie Wittenborg, BS Pharm; Erin Kelley, PharmD, BCOP; Tori Grier, PharmD; Alicia L. Zagel, PhD, MPH; Ann McNamara, PharmD

BACKGROUND

 Oral oncology medications may diminish disease progression and improve overall survival.

.

.

.

.....

- They are <u>expensive</u>, entail <u>complex</u> regimens, and their adverse effects are prevalent and often serious.
- Fairview Specialty Pharmacy has strict processes overseen by oncology pharmacists and liaisons who regularly engage with patients and providers to:
 - Ensure patients take medications correctly,
 - Provide strategies to minimize side effects, and
 - Assess patient medication inventory
- One goal of these processes is to decrease total costs to the pharmacy, patients, and payers.

OBJECTIVE

To **describe interventions** that reduce oral oncology medication waste, and calculate total cost avoidance due to specialty pharmacy processes.

METHODS

Retrospective study of inventory management interventions by oncology pharmacists and liaisons occurring between April 2023 and March 2024.

Documented situations where the full amount of oncology medication was not dispensed at the expected time of refill.

Tracked rationale for the deviation from expected fill, medication and strength, and amount not dispensed

Cost avoidance calculated based on average wholesale medication price (AWP).


Fairview

Fairview Pharmacy Services, Minneapolis, MN

	RESULTS	5		● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●		
INVENTORY MANAGEME	NT INTERVENTIONS AND RATIONA	LE RESUI	_TING IN O	COST AVC	DIDANCE	-
Pharmacist Intervention Category	Rationale	Frequency	Total Cost by Rationale		Total Cost by Category	Avg Cost by Category
Hold or delay dispense	High likelihood of medication or dose change Medication on hold	25 12	\$346,387 \$140,352	\$13,855 \$11,696	\$617,314	\$12,104
Quantity adjustment based on cycle and/or quantity on hand	Excess supply from previous cycle or fill Excess supply from previous cycle or fill	14 26	\$130,575 \$78,971	\$9,327 \$3,037	\$145,801	\$4,288
	High likelihood of medication or dose change Medication on hold	<u> </u>	\$66,830 \$-	\$8,354 \$-		
Proactive split fill	High likelihood of medication or dose change	17	\$111,058	\$6,533	\$111,058	\$6,533
Dose Optimization	Consolidating a patient's regimen into fewer units while providing the appropriate, prescribed dose	2	\$35,712	\$17,856	\$35,712	\$17,856
	Total Pharmacist Interventions:	104	· 		\$909,885	\$8,749

			Total Cost	Avg Cost by	Total Cost by	Avg Cost by
Liaison Intervention Category	Rationale	Frequency	by Rationale	Rationale	Category	Category
Hold or delay dispense	Excess supply from previous cycle or fill	1	\$38,918	\$38,918	\$46,984	\$23,492
	High likelihood of medication or dose change	1	\$8,066	\$8,066		
Quantity adjustment based on cycle and/or quantity on hand	Excess supply from previous cycle or fill	14	\$188,245	\$13,446	\$188,245	\$13,446
	Total Liaison Interventions:	16			\$235,229	\$14,702
	Total Inventory Management Interventions:	120			\$1,145,114	\$9,543

TOP MEDICATIONS INVOLVED IN INVENTORY MANAGEMENT INTERVENTIONS



BY COST AVOIDANCE PER DISPENSE (Among medications with >30 dispenses per year) Cost Avoidance Interventions Cost Avoidance per Intervention per Dispense per Dispens 6.5% \$ 1,919 29,429 Inqovi \$ 1,502 36.809 4.1% Xospata 22,466 5.1% \$ 1,152 Onurea 26,477 \$ 630 2.4% Pigray 12,841 3.4% \$ 443 11,424 3.1% \$ 359 Brukinsa \$ 288 14,402 2.0% Mekinis 8,600 2.3% \$ 196 Kisqal 6,832 2.7% \$ 187 Zejula 6,768 \$ 176 2.6% Tafinlar

DISCUSSION

- There were 120 interventions resulting in >\$1.1 million of cost avoidance in one year.
- Pharmacists made most of the interventions compared to liaisons (87% vs. 13%).
- Top reasons for not dispensing full medication amounts included:
 - high likelihood of medication or dose change (N=51) interventions; \$532,341)
 - excess supply from previous cycle (N=55; \$436,709).

By Medication:

Highest total cost avoidance:

Greatest frequency of interventions:

Highest avg cost avoi per intervention:

Highest intervention rate:

though was rare (N=2).

CONCLUSION

- interventions..



	Verzenio	
	\$99,487	
F	capecitabine/Xeloda	
	22, 19% of total interventions	
dance	Xospata	
	\$36,809	
	Inqovi	
	6.5% of all dispenses	

Consolidating a patient's regimen into fewer higher-strength units while providing the equivalent prescribed dose led to the highest average cost savings at \$17,856 per intervention,

Strict inventory management processes led to significant cost avoidance and reduced waste for oncology medications. Strong engagement with patients and providers is necessary to avoid excess costs or waste and ensure patients have appropriate supply of oral oncology medications. In some cases, access to the medical record may equip the pharmacist with information to allow for additional